WASHINGTON – In a significant ruling on Thursday, the U.S. Supreme Court upheld women’s access to mifepristone, a medication commonly used in the abortion process. This decision comes amidst ongoing legal challenges and aims to protect the availability of the drug while a related lawsuit progresses through the judicial system.
The court’s ruling allows women to continue obtaining mifepristone at pharmacies or through mail services, eliminating the necessity for an in-person consultation with a healthcare provider. This means that access to the medication is likely to remain uninterrupted well into next year as the legal battle unfolds, which may include further appeals to the Supreme Court.
The justices responded to emergency requests from the manufacturers of mifepristone, who are contesting a federal appeals court ruling that mandated in-person consultations and restricted mail delivery of the drug. Notably, the Food and Drug Administration (FDA) had previously eased restrictions, allowing remote consultations five years ago.
Dissenting opinions were voiced by Justices Clarence Thomas and Samuel Alito. Justice Thomas criticized the manufacturers, Danco Laboratories and GenBioPro, arguing that they should not benefit from what he described as “lost profits from their criminal enterprise.”
Anti-abortion advocates, frustrated by the pace of the FDA’s review process under the Trump administration, have been lobbying for more stringent regulations on mifepristone, including a ban on its prescription via telehealth services. The Trump administration, however, has stated that these regulatory processes require time.
This week, FDA Commissioner Marty Makary resigned following sustained criticism from Trump’s political allies, including those opposing abortion rights, who had previously urged the president to dismiss him over the perceived slow progress on mifepristone.
The Supreme Court’s latest ruling arrives four years after it overturned Roe v. Wade, a landmark decision that had previously protected abortion rights, and allowed numerous states to impose comprehensive bans on the procedure.
The case currently under consideration originated from a lawsuit filed by Louisiana, which sought to challenge the FDA’s regulations governing the prescription of mifepristone. The state claimed that these policies conflicted with its own abortion ban and raised concerns regarding the drug’s safety—despite the FDA’s consistent affirmation of its safety and efficacy.
Justice Alito, who authored the opinion that led to the overturning of Roe, noted that Louisiana’s attempts to restrict access to mifepristone have been hindered by medical providers and organizations that continue to supply the drug to women in the state, despite existing bans. He emphasized the awareness of the manufacturers regarding the legality of their actions in Louisiana.
Moreover, Justice Thomas pointed out that mailing mifepristone could violate the Comstock Act, a long-standing law that prohibits the mailing of items intended for use in producing abortions.
Previous lower court rulings indicated that Louisiana was likely to succeed in its case, leading to a significant ruling from the 5th U.S. Circuit Court of Appeals that called for halting mail access and telehealth consultations while the lawsuit is pending.
Mifepristone is commonly used in conjunction with another medication, misoprostol, in medical abortions, which accounted for nearly two-thirds of all abortions performed in the U.S. in 2023, according to the latest statistics.
This ongoing case mirrors a similar dispute that reached the Supreme Court three years ago, when lower courts also sought to limit access to mifepristone following the overturning of Roe.
In that earlier instance, the Supreme Court blocked a ruling from the 5th Circuit that would have restricted access, despite dissenting opinions from Justices Alito and Thomas. Ultimately, in 2024, the court dismissed a related lawsuit filed by physicians opposed to abortion, determining that they lacked the legal standing to bring the case.
In the current dispute, mainstream medical organizations, pharmaceutical companies, and Democratic lawmakers have cautioned the court against implementing restrictions on mifepristone. These stakeholders argue that a ruling favoring abortion opponents could significantly disrupt the drug approval process.
The debate surrounding the safety and efficacy of mifepristone has persisted for over two decades. The FDA has relaxed several initial restrictions on the drug, including expanding who may prescribe it and how it is dispensed.
Despite the FDA’s findings, anti-abortion advocates have continued to file multiple petitions and lawsuits against the agency, alleging violations of federal law regarding the drug’s safety.
The Trump administration has remained notably silent during the Supreme Court proceedings, refraining from submitting a brief regarding the court’s potential actions, despite the fact that federal regulations are central to the case.
This case presents a challenging scenario for the administration, which has relied heavily on the backing of anti-abortion groups while also recognizing that public opinion generally favors abortion rights, as seen in ballot measures and polls.
Both sides interpreted the administration’s lack of a formal stance as a tacit endorsement of the appellate ruling.
___
Mulvihill reported from Haddonfield, N.J.
___
